Generic Name and Formulations:
Chlorzoxazone 375mg, 750mg+; tabs; +scored.
Various generic manufacturers
Indications for Chlorzoxazone:
As adjunct to rest, physical therapy, and other measures in acute, painful musculoskeletal conditions.
375mg: 1 tab 3–4 times daily; may increase to 2 tabs (750mg) 3–4 times daily if inadequate response. 750mg: ⅓ tab (250mg) 3–4 times daily. Painful musculoskeletal conditions: initially ⅔ tab (500mg) 3–4 times daily; may increase to 1 tab (750mg) 3–4 times daily if inadequate response. May reduce dose based on improvement.
Known drug intolerance.
Monitor for hepatotoxicity; discontinue if hepatic dysfunction or abnormal liver enzymes develop. Known allergies or history of. Discontinue if sensitivity reaction occurs. Pregnancy.
Muscle relaxant (central).
Additive effects with concomitant alcohol, other CNS depressants.
Drowsiness, dizziness, lightheadedness, malaise, overstimulation; rare: skin rash, petechiae, ecchymosis, fatal hepatocellular toxicity.
Formerly known under the brand name Lorzone, Paraflex.
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Comparing Osteoporosis Screening, Treatment Strategies in Postmenopausal Women
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Cerebral Small Vessel Disease More Common in Individuals With T1D vs General Population
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners